Safety of elevated pulmonary doses from [177Lu]Lu-PSMA-617 and 90Y-radioembolization therapies

被引：0
|
作者：
Jain, S. [1 ]
Graves, S. A. [1 ]
机构：
[1] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-1229
引用
收藏
页码：S919 / S919
页数：1
相关论文
共 50 条
  • [21] Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617
    Kunikowska, Jolanta
    Charzynska, Ingeborga
    Kulinski, Radoslaw
    Pawlak, Dariusz
    Maurin, Michal
    Krolicki, Leszek
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (06) : 1605 - 1606
  • [22] Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617
    Jolanta Kunikowska
    Ingeborga Charzyńska
    Radosław Kuliński
    Dariusz Pawlak
    Michał Maurin
    Leszek Królicki
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 1605 - 1606
  • [23] Administration of [177Lu] Lu-PSMA-617: Validation of a new method and first-experience
    Santos Virosta, M.
    Romero Zayas, I.
    Campos Anon, F.
    Paredes Barranco, P.
    Cordon Del Pozo, J.
    Fritsch Medina, A.
    Casanueva Eliceiry, S.
    Tormo Ratera, M.
    Quintero Martinez, K.
    Fuster Pelfort, D.
    Agusti, E.
    Rochera Alba, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S652 - S652
  • [24] [177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography
    Toennesmann, Roswitha
    Meyer, Philipp T.
    Eder, Matthias
    Baranski, Ann-Christin
    PHARMACEUTICALS, 2019, 12 (01)
  • [25] Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy
    Rosar, Florian
    Hau, Fabian
    Bartholoma, Mark
    Maus, Stephan
    Stemler, Tobias
    Linxweiler, Johannes
    Ezziddin, Samer
    Khreish, Fadi
    THERANOSTICS, 2021, 11 (09): : 4050 - 4060
  • [26] Predicting benefit from [177Lu]Lu-PSMA-617 therapy: what do we need to know?
    Sartor, Oliver
    LANCET ONCOLOGY, 2022, 23 (11): : 1344 - 1345
  • [27] Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [177Lu]Lu-PSMA-617
    Martin, Sebastian
    Tonnesmann, Roswitha
    Hierlmeier, Ina
    Maus, Stephan
    Rosar, Florian
    Ruf, Juri
    Holland, Jason P.
    Ezziddin, Samer
    Bartholoma, Mark D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (08) : 4960 - 4971
  • [28] Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial
    Herrmann, Ken
    Gafita, Andrei
    de Bono, Johann S.
    Sartor, Oliver
    Chi, Kim N.
    Krause, Bernd J.
    Rahbar, Kambiz
    Tagawa, Scott T.
    Czernin, Johannes
    El-Haddad, Ghassan
    Wong, Connie C.
    Zhang, Zhaojie
    Wilke, Celine
    Mirante, Osvaldo
    Morris, Michael J.
    Fizazi, Karim
    ECLINICALMEDICINE, 2024, 77
  • [29] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment
    Todenhoefer, Tilman
    AKTUELLE UROLOGIE, 2023, 54 (04)
  • [30] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
12345